Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort

Abstract

Purpose

To investigate the long-term safety (primary endpoint) and effectiveness (secondary endpoint) of the somatropin biosimilar Omnitrope®.

Methods

PATRO Children is an ongoing, multicenter, observational, post-marketing surveillance study. Children who received Omnitrope® for any indication were included. Adverse events (AEs) were evaluated in all study participants. Auxological data, including height standard deviation scores (HSDS) and height velocity standard deviation scores (HVSDS), were used to assess effectiveness. In this snapshot analysis, data from the Italian subpopulation up to August 2017 were reported.

Results

A total of 291 patients (mean age 10.0 years, 56.0% male) were enrolled at 19 sites in Italy. The mean duration of Omnitrope® treatment was 33.1 ± 21.7 months. There were 48 AEs with a suspected relationship to the study drug (as reported by the investigator) that occurred in 35 (12.0%) patients, most commonly headache, pyrexia, arthralgia, insulin-like growth factor above normal range, abdominal pain, pain in extremity and acute gastroenteritis. There were no confirmed cases of type 1 or type 2 diabetes; however, two patients (0.7%) had impaired glucose tolerance that was considered Omnitrope® related. The mean HSDS increased from − 2.41 ± 0.73 at baseline (n = 238) to − 0.91 ± 0.68 at 6.5 years (n = 10). The mean HVSDS increased from − 1.77 ± 1.38 at baseline (n = 136) to 0.96 ± 1.13 at 6.5 years (n = 10).

Conclusions

In this sub-analysis of PATRO Children, Omnitrope® appeared to have acceptable safety and effectiveness in the treatment of in Italian children, which was consistent with the earlier findings from controlled clinical trials.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. 1.

    Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen J, Cianfarani S, Clayton P, Clemmons D, Cohen P, Darendeliler F, Deal C, Dunger D, Erfurth EM, Fuqua JS, Grimberg A, Haymond M, Higham C, Ho K, Hoffman AR, Hokken-Koelega A, Johannsson G, Juul A, Kopchick J, Lee P, Pollak M, Radovick S, Robison L, Rosenfeld R, Ross RJ, Savendahl L, Saenger P, Toft Sorensen H, Stochholm K, Strasburger C, Swerdlow A, Thorner M (2016) GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol 174(2):1–9. https://doi.org/10.1530/EJE-15-0873

    CAS  Article  Google Scholar 

  2. 2.

    Cook DM, Rose SR (2012) A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary 15(3):301–310. https://doi.org/10.1007/s11102-011-0372-6

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH (2016) Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 86(6):361–397. https://doi.org/10.1159/000452150

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    European Medicines Agency (2017) Omnitrope®: summary of product characteristics. https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000607/WC500043695.pdf. Accessed 15 Dec 2017

  5. 5.

    López-Siguero J, Borrás Pérez MV, Balser S, Khan-Boluki J (2011) Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study. Adv Ther 28(10):879–893. https://doi.org/10.1007/s12325-011-0063-8

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Romer T, Saenger P, Peter F, Walczak M, Le Bouc Y, Khan-Boluki J, Berghout A (2009) Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of growth hormone deficient children: results of a phase III study. Horm Res 72(6):359–369. https://doi.org/10.1159/000249164

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Pfäffle R, Schwab KO, Marginean O, Walczak M, Szalecki M, Schuck E, Zabransky M, Zucchini S (2013) Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® in children requiring growth hormone treatment. Ther Adv Endocrinol Metab 4(1):3–11. https://doi.org/10.1177/2042018813479644

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Pfaffle R, Kanumakala S, Hoybye C et al (2015) Results up to January 2015 from PATRO Children, a multi-centre, noninterventional study of the long-term safety and efficacy of Omnitrope® in children requiring GH treatment. Horm Res Paediatr 84(Suppl 1):242–248

    Google Scholar 

  9. 9.

    Pfäffle R, Kanumakala S, Hoybye C et al (2016) Four-year results from PATRO Children, a multi-centre, non-interventional study of the long-term safety and efficacy of Omnitrope® in children requiring growth hormone treatment. ESPE Abstr 86:1–634

    Google Scholar 

  10. 10.

    Iughetti L, Tornese G, Street ME, Napoli F, Giavoli C, Antoniazzi F, Stagi S, Luongo C, Azzolini S, Ragusa L, Bona G, Zecchino C, Aversa T, Persani L, Guazzarotti L, Zecchi E, Pietropoli A, Zucchini S (2016) Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study. Ital J Pediatr 42(1):93. https://doi.org/10.1186/s13052-016-0302-3

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Bertino E, Spada E, Occhi L, Coscia A, Giuliani F, Gagliardi L, Gilli G, Bona G, Fabris C, De Curtis M, Milani S (2010) Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr 51(3):353–361. https://doi.org/10.1097/MPG.0b013e3181da213e

    Article  PubMed  Google Scholar 

  12. 12.

    Tanner JM, Whitehouse RH (1976) Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51(3):170–179

    CAS  Article  Google Scholar 

  13. 13.

    Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, Price DA (2000) Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 355(9204):610–613. https://doi.org/10.1016/S0140-6736(99)04055-6

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Fuhr U, Tuculanu D, Berghout A, Balser S, Schwebig A, Saenger P (2010) Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin. Eur J Endocrinol 162(6):1051–1058. https://doi.org/10.1530/eje-09-1101

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Romer T, Peter F, Saenger P, Starzyk J, Koehler B, Korman E, Walczak M, Wasik R, Ginalska-Malinowska M, Solyom E, Berghout A (2007) Efficacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest 30(7):578–589

    CAS  Article  Google Scholar 

  16. 16.

    Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB (2006) Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 91(6):2047–2054. https://doi.org/10.1210/jc.2005-2284

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

Medical writing assistance in drafting the outline and first draft of this manuscript was provided by Matt Shirley and Mimi Chan, PhD, of Springer Healthcare Communications, respectively. This medical writing assistance was funded by Sandoz, Italy.

Funding

The study was funded by Sandoz, Italy.

Author information

Affiliations

Authors

Contributions

LP, LP, and NAG enrolled patients, and read and approved the manuscript drafts. SZ and LI contributed to study design, enrolled patients, and critically revised the manuscript.FA, GB, TA, LG, RM, GP, LR, SS, GT, PG, HZ, PF, and CZ contributed to the drafting of the manuscript, critically revised the various drafts of the manuscript, read and approved the final version before submission. CG enrolled patients, critically revised the various drafts of the manuscript, and read and approved the final version before submission.

Corresponding author

Correspondence to L. Iughetti.

Ethics declarations

Conflict of interest

LI has participated in Advisory Boards for Eli Lilly, Italy and Novo Nordisk, Italy; FA has received honoraria from Eli Lilly, Novo Nordisk and Ipsen and research funding from Merck Serono; CG, TA, NAG, LG, RM, L Perrone, LR, SS, and GT have no conflict of interest to declare; L Persani has been an invited speaker for Sandoz and Merck-Serono, and has received unconditional research funds from Novartis, IBSA and Merck-Serono; GB has received honoraria from Ferring, Novo, Serono, Lilly, Sandoz; CZ has received honoraria from Sandoz, Novo, Medtronic; HZ is an employee of Sandoz Biopharmaceutical c/o HEXAL AG, Germany; PG and PF are employees of Sandoz S.p.A, Milan, Italy; SZ has been a member of expert committees for Eli Lilly Diabetes, Italy, and Roche Diagnostics.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Comitato Etico Indipendente dell’Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, n°120/2007/O/Oss) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the parents or legal guardians of all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Iughetti, L., Antoniazzi, F., Giavoli, C. et al. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort. J Endocrinol Invest (2020). https://doi.org/10.1007/s40618-020-01331-4

Download citation

Keywords

  • Adolescents
  • Children
  • Infants
  • Omnitrope®
  • Pediatric
  • Recombinant human growth hormone